首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2期丙型肝炎的治疗 => 专家论坛 =>我国慢性丙型肝炎患者真实世界中直接抗病毒..
我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价
Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China
文章发布日期:2018年01月05日  来源:  作者:安子英,丁洋,窦晓光  点击次数:627次  下载次数:180次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:慢性丙型肝炎是一种世界范围流行的慢性进展性疾病,严重威胁人类健康,直接抗病毒药物(DAA)的上市为其治疗带来了革命性的变化。近年来国外已上市多种DAA并取得了良好的疗效,我国亦已陆续批准上市数种并广泛应用于临床,使丙型肝炎治愈率显著上升。通过对我国已上市药物的特点、临床疗效及适应证进行分析,结合已经发表的真实世界中的研究,帮助临床医生根据患者疾病的特点,选择合适的治疗方案。
【Abstract】:Chronic hepatitis C (CHC) is a chronic and progressive disease prevalent in the whole world and greatly threatens human health. The launch of direct-acting antiviral agents (DAAs) brings a revolutionary change in the treatment of CHC. In recent years, several DAAs have been marketed in foreign countries and have achieved good clinical effects, and in China, some DAAs have also been approved and widely used in clinical practice, which contributes to the increase in the cure rate of hepatitis C. This article analyzes the features, clinical effects, and indications of DAAs marketed in China and reviews published real-world studies, in order to help clinicians select proper treatment regimens based on patients′ features.
【关键字】:肝炎, 丙型, 慢性; 抗病毒药; 治疗; 真实世界
【Key words】:hepatitis C, chronic; antiviral agents; therapy; real-world
【引证本文】:AN ZY, DING Y, DOU XG. Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China[J]. J Clin Hepatol, 2018, 34(2): 233-237. (in Chinese)
安子英, 丁洋, 窦晓光. 我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价[J]. 临床肝胆病杂志, 2018, 34(2): 233-237.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号